BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tran-duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016;14:1706-1719.e5. [DOI: 10.1016/j.cgh.2016.05.018] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 14.7] [Reference Citation Analysis]
Number Citing Articles
1 Arai J, Niikura R, Hayakawa Y, Sato H, Kawahara T, Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Ikeya T, Arai M, Suzuki N, Tsuji Y, Yamada A, Koike K. Nonsteroidal anti-inflammatory drugs prevent gastric cancer associated with the use of proton pump inhibitors after Helicobacter pylori eradication. JGH Open 2021;5:770-7. [PMID: 34263071 DOI: 10.1002/jgh3.12583] [Reference Citation Analysis]
2 Helgadottir H, Bjornsson ES. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci 2019;20:E5469. [PMID: 31684070 DOI: 10.3390/ijms20215469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Hwang IC, Chang J, Park SM. Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study. PLoS One 2018;13:e0203918. [PMID: 30208110 DOI: 10.1371/journal.pone.0203918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
4 Zhou C, Fang J. Several aspects in study design need further consideration. Gut 2018;67:2070-1. [DOI: 10.1136/gutjnl-2017-315692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Aronson JK. Inhibiting the proton pump: mechanisms, benefits, harms, and questions. BMC Med 2016;14:172. [PMID: 27825384 DOI: 10.1186/s12916-016-0724-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 MacArthur TA, Harmsen WS, Mandrekar J, Abraha F, Grotz TE. Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study. J Cancer Epidemiol 2021;2021:2670502. [PMID: 34899912 DOI: 10.1155/2021/2670502] [Reference Citation Analysis]
7 Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67:28-35. [PMID: 29089382 DOI: 10.1136/gutjnl-2017-314605] [Cited by in Crossref: 195] [Cited by in F6Publishing: 166] [Article Influence: 39.0] [Reference Citation Analysis]
8 Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020;51:505-526. [PMID: 31990420 DOI: 10.1111/apt.15604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
9 Gueta I, Halkin H, Markovits N, Loebstein R. Proton pump inhibitors and the risk for gastric cancer: possible confounding by serum vitamin B12. Gut. 2017; Epub ahead of print. [PMID: 29183922 DOI: 10.1136/gutjnl-2017-315695] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sano W, Inoue F, Hirata D, Iwatate M, Hattori S, Fujita M, Sano Y. Sporadic fundic gland polyps with dysplasia or carcinoma: Clinical and endoscopic characteristics. World J Gastrointest Oncol 2021; 13(7): 662-672 [PMID: 34322195 DOI: 10.4251/wjgo.v13.i7.662] [Reference Citation Analysis]
11 Fukuda M, Ishigaki H, Sugimoto M, Mukaisho KI, Matsubara A, Ishida H, Moritani S, Itoh Y, Sugihara H, Andoh A, Ogasawara K, Murakami K, Kushima R. Histological analysis of fundic gland polyps secondary to PPI therapy. Histopathology. 2019;75:537-545. [PMID: 31087669 DOI: 10.1111/his.13902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
12 Cheung KS, Leung WK. Risk of gastric cancer development after eradication of Helicobacter pyloriWorld J Gastrointest Oncol 2018; 10(5): 115-123 [PMID: 29770171 DOI: 10.4251/wjgo.v10.i5.115] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
13 Cheesman AR, Greenwald DA, Shah SC. Current Management of Benign Epithelial Gastric Polyps. Curr Treat Options Gastro 2017;15:676-90. [DOI: 10.1007/s11938-017-0159-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
14 Baker JR, Sakoff JA, McCluskey A. The aryl hydrocarbon receptor (AhR) as a breast cancer drug target. Med Res Rev 2020;40:972-1001. [PMID: 31721255 DOI: 10.1002/med.21645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
15 Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety 2018;17:785-94. [DOI: 10.1080/14740338.2018.1497155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
16 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
17 Turner KO, Lindberg GM, Genta RM. Gastric granulomas and Helicobacter pylori: An incidental relationship. Helicobacter 2021;26:e12805. [PMID: 33843096 DOI: 10.1111/hel.12805] [Reference Citation Analysis]
18 Costa P, Boeing T, Somensi LB, Cury BJ, Espíndola VL, França TCS, Almeida MO, Arruda C, Bastos JK, Silva LM, Andrade SF. Hydroalcoholic extract from Baccharis dracunculifolia recovers the gastric ulcerated tissue, and p ‐coumaric acid is a pivotal bioactive compound to this action. BioFactors 2019;45:479-89. [DOI: 10.1002/biof.1503] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
19 Joo MK, Park JJ, Chun HJ. Proton pump inhibitor: The dual role in gastric cancer. World J Gastroenterol 2019; 25(17): 2058-2070 [PMID: 31114133 DOI: 10.3748/wjg.v25.i17.2058] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
20 Segna D, Brusselaers N, Glaus D, Krupka N, Misselwitz B. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211051463. [PMID: 34777575 DOI: 10.1177/17562848211051463] [Reference Citation Analysis]
21 Cheung KS, Chan EW, Wong AYS, Chen L, Seto WK, Wong ICK, Leung WK. Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication. J Natl Cancer Inst. 2019;111:484-489. [PMID: 30329127 DOI: 10.1093/jnci/djy144] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
22 Helgadóttir H, Lund SH, Gizurarson S, Metz DC, Björnsson ES. Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy. J Clin Gastroenterol 2020;54:227-34. [PMID: 30994520 DOI: 10.1097/MCG.0000000000001200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
23 Veettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P, Lee YY, Nair AB, Antony PT, Ford AC, Chaiyakunapruk N. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol 2021. [PMID: 34622475 DOI: 10.1111/bcp.15103] [Reference Citation Analysis]
24 Pinto G, Colombo B, Autieri A, Foppoli L, Spoladore R, Ardizzone V, Margonato A, Corti A, Fragasso G. Vasostatin-1 as a potential novel circulating biomarker in patients with chronic systolic heart failure: A pilot study. Clin Chim Acta 2021;526:49-54. [PMID: 34973182 DOI: 10.1016/j.cca.2021.12.024] [Reference Citation Analysis]
25 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 72] [Article Influence: 19.2] [Reference Citation Analysis]
26 Snir Y, Leibovitzh H, Leibovici-Weissman Y, Vilkin A, Cohen AD, Shochat T, Niv Y, Dotan I, Feldhamer I, Boltin D, Levi Z. Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients. United European Gastroenterol J 2021;9:343-53. [PMID: 32962566 DOI: 10.1177/2050640620951403] [Reference Citation Analysis]
27 Abbas MK, Zaidi ARZ, Robert CA, Thiha S, Malik BH. The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review. Cureus 2019;11:e5563. [PMID: 31523592 DOI: 10.7759/cureus.5563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
28 Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Current Opinion in Gastroenterology 2017;33:430-8. [DOI: 10.1097/mog.0000000000000392] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
29 Jiang K, Jiang X, Wen Y, Liao L, Liu F. Relationship between long‐term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. Journal of Gastroenterology and Hepatology 2019;34:1898-905. [DOI: 10.1111/jgh.14759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
30 Mohammed A, Garg R, Trakroo S, Singh A, Sanaka MR. Long term outcomes of sporadic large fundic gland polyps: a single-center experience. Scand J Gastroenterol 2021;56:1391-5. [PMID: 34415799 DOI: 10.1080/00365521.2021.1968032] [Reference Citation Analysis]
31 Rudloff U. Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. Clin Exp Gastroenterol. 2018;11:447-459. [PMID: 30584346 DOI: 10.2147/ceg.s163227] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
32 Khalaf M, Brock AS, Castell D. Sporadic Fundic Gland Polyps and Gastric Acid Suppression Level. Am J Med Sci 2017;354:561-4. [PMID: 29208252 DOI: 10.1016/j.amjms.2017.07.009] [Reference Citation Analysis]
33 Orr CE, Beneck D, Jessurun J, Qin L, Tyryshkin K, Yantiss RK, Chen YT. High interobserver variability and frequent overdiagnosis of dysplasia in fundic gland polyps can be improved by detecting atypia on the surface epithelium and an abrupt transition to non-neoplastic cells. Histopathology 2021. [PMID: 34424570 DOI: 10.1111/his.14549] [Reference Citation Analysis]
34 Fukuda M, Ishigaki H, Ban H, Sugimoto M, Tanaka E, Yonemaru J, Kuroe S, Namura T, Matsubara A, Moritani S, Murakami K, Andoh A, Kushima R. No transformation of a fundic gland polyp with dysplasia into invasive carcinoma after 14 years of follow-up in a proton pump inhibitor-treated patient: A case report. Pathol Int. 2018;68:706-711. [PMID: 30511782 DOI: 10.1111/pin.12739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
36 Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis. 2020;52:842-852. [PMID: 32513631 DOI: 10.1016/j.dld.2020.04.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
37 Zhu L, Zhu L, Yu W. Analysis of pathological characteristics and nursing intervention of patients with gastric polyps based on image stitching algorithm and endoscopy. Pak J Med Sci 2021;37:1620-4. [PMID: 34712294 DOI: 10.12669/pjms.37.6-WIT.4854] [Reference Citation Analysis]
38 Buzás GM. Benign and malignant gastroduodenal diseases associated with Helicobacter pylori: a narrative review and personal remarks in 2018. Minerva Gastroenterol Dietol 2018;64:280-96. [PMID: 29458240 DOI: 10.23736/S1121-421X.18.02481-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
39 Uno Y. Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan. Cancer Med 2019;8:3992-4000. [PMID: 31119891 DOI: 10.1002/cam4.2277] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
40 Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol 2019;33:327-38. [PMID: 30625254 DOI: 10.1111/fcp.12436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Durán C, Ciucci S, Palladini A, Ijaz UZ, Zippo AG, Sterbini FP, Masucci L, Cammarota G, Ianiro G, Spuul P, Schroeder M, Grill SW, Parsons BN, Pritchard DM, Posteraro B, Sanguinetti M, Gasbarrini G, Gasbarrini A, Cannistraci CV. Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nat Commun 2021;12:1926. [PMID: 33771992 DOI: 10.1038/s41467-021-22135-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
42 Numico G, Fusco V, Franco P, Roila F. Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use. Critical Reviews in Oncology/Hematology 2017;111:144-51. [DOI: 10.1016/j.critrevonc.2017.01.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
43 Gracie DJ, Ford AC. The possible risks of proton pump inhibitors. Med J Aust 2016;205:292-3. [PMID: 27681962 DOI: 10.5694/mja16.00750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
44 Gesmundo I, Di Blasio L, Banfi D, Villanova T, Fanciulli A, Favaro E, Gamba G, Musuraca C, Rapa I, Volante M, Munegato S, Papotti M, Gontero P, Primo L, Ghigo E, Granata R. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase. Cancer Lett 2019;449:252-62. [PMID: 30790678 DOI: 10.1016/j.canlet.2019.02.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Cooksey R, Kennedy J, Dennis MS, Escott-Price V, Lyons RA, Seaborne M, Brophy S. Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One 2020;15:e0237676. [PMID: 32946449 DOI: 10.1371/journal.pone.0237676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology 2019;69:1151-64. [PMID: 30175498 DOI: 10.1002/hep.30247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
47 Togo K, Ueo T, Yonemasu H, Honda H, Ishida T, Tanabe H, Yao K, Iwashita A, Murakami K. Two cases of adenocarcinoma occurring in sporadic fundic gland polyps observed by magnifying endoscopy with narrow band imaging. World J Gastroenterol 2016; 22(40): 9028-9034 [PMID: 27833394 DOI: 10.3748/wjg.v22.i40.9028] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
48 Jeong CY, Kim N, Lee HS, Yoon H, Shin CM, Park YS, Kim J, Lee DH. Risk Factors of Multiple Gastric Polyps according to the Histologic Classification: Prospective Observational Cohort Study. Korean J Gastroenterol 2019;74:17. [DOI: 10.4166/kjg.2019.74.1.17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
49 Ouyang Y, Zhang W, Huang Y, Wang Y, Shao Q, Wu X, Lu N, Xie C. Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis. Helicobacter 2021;:e12838. [PMID: 34333811 DOI: 10.1111/hel.12838] [Reference Citation Analysis]
50 Broide E, Eindor-Abarbanel A, Shirin H, Richter V, Matalon S, Leshno M. Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice. BMJ Open 2020;10:e031091. [PMID: 32051298 DOI: 10.1136/bmjopen-2019-031091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Song HJ, Jeon N, Squires P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1437-56. [PMID: 32548678 DOI: 10.1007/s00228-020-02927-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
53 Sebastián Domingo JJ. Inhibidores de la bomba de protones y carcinogénesis gástrica. Medicina Clínica 2018;151:400-1. [DOI: 10.1016/j.medcli.2018.03.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Kurlander JE, Kolbe M, Rubenstein JH, Richardson CR, Heisler M, Weissman A, De Vries R, Saini SD. Internists' Perceptions of Proton Pump Inhibitor Adverse Effects and Impact on Prescribing Practices: Results of a Nationwide Survey. Gastroenterology Res 2018;11:11-7. [PMID: 29511400 DOI: 10.14740/gr944w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
55 Cheung KS, Chan EW, Wong AYS, Chen L, Seto WK, Wong ICK, Leung WK. Aspirin and Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study. J Natl Cancer Inst. 2018;110:743-749. [PMID: 29361002 DOI: 10.1093/jnci/djx267] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
56 Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther 2021;54:129-43. [PMID: 34114655 DOI: 10.1111/apt.16407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Joo MK, Park JJ, Chun HJ. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Dig Dis 2018;36:1-14. [PMID: 28881340 DOI: 10.1159/000480149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
58 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
59 Saiz Ladera GM, Pejenaute Labari ME, García Pascual JN. [Updating in prescription of proton pump inhibitors. What to do and what not to do]. Semergen 2021;47:267-79. [PMID: 33223372 DOI: 10.1016/j.semerg.2020.09.011] [Reference Citation Analysis]
60 Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use: Proton pump inhibitors. Journal of Gastroenterology and Hepatology 2017;32:1295-302. [DOI: 10.1111/jgh.13737] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
61 Boyce M, Lloyd KA, Pritchard DM. Potential clinical indications for a CCK2 receptor antagonist. Current Opinion in Pharmacology 2016;31:68-75. [DOI: 10.1016/j.coph.2016.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
62 Leitinger E, Hui L, Grigg A. Is there a role for proton pump inhibitor prophylaxis in haematology patients? Intern Med J 2019;49:694-701. [PMID: 30719802 DOI: 10.1111/imj.14241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Liu P, McMenamin ÚC, Johnston BT, Murchie P, Iversen L, Lee AJ, Vissers PAJ, Cardwell CR. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. Br J Cancer 2020;123:307-15. [PMID: 32367073 DOI: 10.1038/s41416-020-0860-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 Fisher L, Fisher A, Smith PN. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). J Clin Med 2020;9:E3253. [PMID: 33053671 DOI: 10.3390/jcm9103253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Lock G, Oelckers M, Clauditz TS, Schrader J. Gastric NET Subtypes: Do We Need An Additional One? Z Gastroenterol 2021;59:255-8. [PMID: 33506449 DOI: 10.1055/a-1348-2727] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Ngamruengphong S, Abe S, Oda I. Endoscopic Management of Early Gastric Adenocarcinoma and Preinvasive Gastric Lesions. Surg Clin North Am 2017;97:371-85. [PMID: 28325192 DOI: 10.1016/j.suc.2016.11.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
67 Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: A review of the current evidence. Therap Adv Gastroenterol. 2019;12:1756284819834511. [PMID: 30886648 DOI: 10.1177/1756284819834511] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
68 Kim GH. Proton Pump Inhibitor-Related Gastric Mucosal Changes. Gut Liver 2021;15:646-52. [PMID: 32327613 DOI: 10.5009/gnl20036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
69 Tran-Duy A, Connell NJ, Vanmolkot FH, Souverein PC, de Wit NJ, Stehouwer CDA, Hoes AW, de Vries F, de Boer A. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J Intern Med 2019;285:205-14. [PMID: 30141278 DOI: 10.1111/joim.12826] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
70 Velazquez-Dohorn M, López-Durand CF, Candanedo-González F, Araujo-Villalvazo EA, Gamboa-Domínguez A. Case-control analysis of fundic gland polyps and proton-pump inhibitors. A pathologist's perspective. Rev Gastroenterol Mex (Engl Ed) 2020;85:42-7. [PMID: 31126726 DOI: 10.1016/j.rgmx.2019.02.007] [Reference Citation Analysis]
71 Zhang C, Gao F, Gan S, He Y, Chen Z, Liu X, Fu C, Qu Y, Zhang J. Chemical characterization and gastroprotective effect of an isolated polysaccharide fraction from Bletilla striata against ethanol-induced acute gastric ulcer. Food and Chemical Toxicology 2019;131:110539. [DOI: 10.1016/j.fct.2019.05.047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
72 Lam SK, Lau GKK. Idiopathic multitudinous fundic gland polyposis: A new disease and a management dilemma. JGH Open 2021;5:525-7. [PMID: 33860106 DOI: 10.1002/jgh3.12496] [Reference Citation Analysis]
73 Olufajo OA, Wilson A, Yehayes B, Zeineddin A, Cornwell EE, Williams M. Trends in the Surgical Management and Outcomes of Complicated Peptic Ulcer Disease. Am Surg 2020;86:856-64. [PMID: 32916073 DOI: 10.1177/0003134820939929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Elias E, Targownik LE. The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events. Drugs 2019;79:715-31. [PMID: 30972661 DOI: 10.1007/s40265-019-01110-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
75 Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016;44:915-925. [PMID: 27634363 DOI: 10.1111/apt.13800] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
76 Huang L, Qi DJ, He W, Xu AM. Omeprazole promotes carcinogenesis of fore-stomach in mice with co-stimulation of nitrosamine. Oncotarget 2017;8:70332-44. [PMID: 29050283 DOI: 10.18632/oncotarget.19696] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
77 Monteiro RLR, Kobayasi MAMR, Araujo MR, Monteiro DR, Andreollo NA. Omeprazole and adenocarcinoma in the stomach of rats submitted to duodenogastric reflux. Is there a protective effect? Acta Cir Bras 2020;35:e202000904. [PMID: 33027361 DOI: 10.1590/s0102-865020200090000004] [Reference Citation Analysis]
78 Nawata Y, Ichihara S, Hirasawa D, Tanaka I, Unno S, Igarashi K, Matsuda T. A case of gastric adenocarcinoma considered to originate from a sporadic fundic gland polyp in a Helicobacter pylori-uninfected stomach. Clin J Gastroenterol. 2020;13:740-745. [PMID: 32468503 DOI: 10.1007/s12328-020-01139-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Malfertheiner P, Venerito M, Schulz C. Helicobacter pylori Infection: New Facts in Clinical Management. Curr Treat Options Gastroenterol. 2018;16:605-615. [PMID: 30415359 DOI: 10.1007/s11938-018-0209-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
80 Palmer RH. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2017;15:790. [DOI: 10.1016/j.cgh.2016.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
81 Tantai XX, Yang LB, Wei ZC, Xiao CL, Chen LR, Wang JH, Liu N. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25(21): 2683-2698 [PMID: 31210719 DOI: 10.3748/wjg.v25.i21.2683] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
82 McCarthy DM. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? Int J Mol Sci 2020;21:E662. [PMID: 31963924 DOI: 10.3390/ijms21020662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
83 Kishikawa H, Ojiro K, Nakamura K, Katayama T, Arahata K, Takarabe S, Miura S, Kanai T, Nishida J. Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication. Helicobacter. 2020;25:e12669. [PMID: 31680399 DOI: 10.1111/hel.12669] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
84 Lee JK, Merchant SA, Schneider JL, Jensen CD, Fireman BH, Quesenberry CP, Corley DA. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol 2020;115:706-15. [DOI: 10.14309/ajg.0000000000000591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
85 Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2021. [PMID: 34807007 DOI: 10.14309/ajg.0000000000001538] [Reference Citation Analysis]
86 Niikura R, Hayakawa Y, Hirata Y, Yamada A, Fujishiro M, Koike K. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. 2017; Epub ahead of print. [PMID: 29273641 DOI: 10.1136/gutjnl-2017-315710] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]